







## AVAILABLE IN LIBREVIEW<sup>+</sup>

## AGP REPORT WITH TIME IN RANGE

Now You Know





The FreeSple Libre 2 flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people aged 4 years and older with diabetes mellitus. The FreeSple Libre flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in adults aged 18 years and older with diabetes mellitus. Always read and follow the label/intert.

The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app.

AGP, ambulatory glucose profile.

\* Based on the number of users worldwide for the FreeStyle Libre systems compared to the number of users for other leading personal use sensor-based glucose monitoring systems.

+ The LibreView website is only compatible with certain operating systems and browsers. Please check www.LibreView.com for additional information 1. Data on file, Abbott: Diabetes Care, Inc.

## Look beyond A1C for the real story behind your patients' glucose results



Decrease Time In Range helps you to quickly assess patients' glucose and contextualise A1C ncrease Time in range by showing the percentage of readings and time per day in and out of range Decrease Time below range

A1C

A1C has limitations. A1C reflects average glucose over the last 2-3 months; it does not show glycemic excursions of hyper- and hypoglycemia<sup>1</sup>



Ambulatory Glucose Profiles reveal glucose trends and patterns at a glance and help identify when patients are out of target range<sup>2</sup>

## EVERY 10% INCREASE IN TIME IN RANGE IS ASSOCIATED WITH A 0.8% DECREASE IN A1C<sup>3</sup>

A single page comprehensive report that displays all the key metrics referred to in the International Consensus on Time in Range guidelines.<sup>1</sup>



## The AGP report shows:



For illustrative purposes only. Not actual patient data.

\* The LibreView website is only compatible with certain operating systems and browsers. Please check www.LibreView.com for additional information.

1. Battelino, T. Diabetes Care (2019): https://doi.org/10.2337/dci19-0028.

# See Time In Range guidelines and an overview of patient glucose data





#### FOR AGE <25 YEARS, IF A1C IS 7.5%, TIME IN RANGE TARGET IS 60%. FOR OLDER/HIGH RISK: >50% OF TIME/DAY IN TARGET RANGE (3.9-10.0 MMOL/L) AND <1% IN TIME BELOW RANGE (3.9 MMOL/L). FOR T1D PREGNANCY: >70% OF TIME/DAY IN TARGET RANGE (3.8-7.8 MMOL/L).

## Quickly assess your patients' Time In Ranges





### THE PRIMARY GOAL FOR EFFECTIVE AND SAFE GLUCOSE CONTROL IS TO INCREASE TIME IN RANGE WHILE REDUCING TIME BELOW RANGE'

## The AGP makes it easy to identify trends and patterns at a glance



#### 3 AMBULATORY GLUCOSE PROFILE (AGP) AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if occurring in a single day. 21.0mmol/L Uncover patterns of hyperglycemia and 13.9 hypoglycemia and see 0 95% glycemic variability 10.0 75% 50% Target Range 25% 3.9-5% 3.0 0.0 00.00 03.00 06.00 09.00 12·00 15.0018.00 21.00 00.00 Hypoglycemia Variability Hyperglycemia Uncover patterns Show how glucose levels vary Identify when patients are out of throughout the day their target range of hypoglycemia

### AGP WHEN USED WITH TIME IN RANGE CAN REVEAL WHEN PATIENTS ARE OUT OF THEIR RANGE

# Identify specific times of deviation with the Daily Glucose Profiles



#### DAILY GLUCOSE PROFILES

Δ

Each daily profile represents a midnight to midnight period with the date displayed in the upper left corner. Wednesday Thursday Friday Saturday Sunday Monday Tuesday 18 19 21 22 23 20 24 10.0 3.9 00.00 12.00 00:00 12.00 00:00 12.00 00.00 12.00 00:00 12:00 00:00 12.00 00:00 12.00 00.00 25 26 27 28 29 30 31 10.0 -3.9

A way for you and your patients to **see specific daily glucose activity,** which could help identify causes for deviations from Time In Range

### USE THESE DAILY GLUCOSE VALUES PROFILES TO HELP GUIDE YOUR PATIENTS THROUGH A CLINICAL AND ENGAGING DIALOGUE





AGP Report 18 March 2020 - 31 March 2020 (14 Days)		LibreView		
GLUCOSE STATISTICS AND TAI	IGETS	TIME IN	RANGES	
18 March 2020 - 31 March 2020 % Time Sensor is Active	14 Days 97%		Very High >128 mmoit.	1% (Senie)
Ranges And Targets For	Type 1 or Type 2 Diabetes	13.9	High 10.1 - 13.9 mmolt.	18% (eh timin)
Glucose Ranges Target Range 3.9-10.0 mmolt. Datas 3.9 mmolt	Targets 's in Readings (Time/Day) Groader than 70% (18h 46min) Less than 4% (56min)	10.0		
Below 1.0 mmoil. Above 10.0 mmoil. Above 11.9 mmoil.	Less than 1% (14min) Less than 25% (6h) Less than 5% (1h 12min)		Target Range 28-100 mmail.	78% (tilh 44mir)
Each 9% increase in time in range (3.9-10.0 m Average Glucose	1011.) is clinically beneficial. 7.8 mmst.	2.9	Low 20-28 most.	3% (43min)
Slucose Management Indicator (C	MI) 6.7% or 49 mmol/mol	20	Very Low <10 mmail.	0% (tmin)
Glucose Variability Defined as percent coefficient of variation (%	32.1% V); target s36%			
AMBULATORY GLUCOSE PROF	ILE (AGP)			





## Make more informed diabetes management decisions\* with the **AGP** report

- Time In Range allows you to quickly assess your patients' time spent above, within, and below target range
- AGP graph helps you see when the patient is out of range
- · Identify glucose trends and patterns at a glance

## Now You Know

## HELP YOUR PATIENTS INCREASE THEIR TIME IN RANGE PRESCRIBE THE FREESTYLE LIBRE FAMILY OF PRODUCTS



For illustrative purposes only. Not actual patient data.

ADC-73104 v1.0

<sup>\*</sup> Treatment decisions should not be based on real-time sensor glucose readings alone but instead should consider all the information on the results screen.

<sup>+</sup> The LibreView website is only compatible with certain operating systems and browsers. Please check www.LibreView.com for additional information

<sup>© 2023</sup> Abbott. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott.